$150M life sciences fund launches; Apricus names new CEO; Study: One in three seniors dies with Alzheimer's;

 @FierceBiotech: FDA staff review raises big questions about fate of Titan's Probuphine. More | Follow @FierceBiotech

@JohnCFierce: Biopharma's Top R&D Spenders - 2012. Special Report | Follow @JohnCFierce

@RyanMFierce: Fierce's top 5 feats in life sciences 'gamification'. Special Report | Follow @RyanMFierce

> Sir Chris Evans' £100 million life sciences fund for Wales has officially opened. It is using £50 million contributed by the Welsh government to encourage regional biotech development. Story

> Apricus Biosciences has named Richard Pascoe as its new CEO. Pascoe is the former CEO of Somaxon, which developed Silenor. Story

> OTC shares of InSite Vision ($INSV) surged this morning after the company reported positive data from a late stage study of BromSite (ISV-303) for the reduction of inflammation and pain after cataract surgery. The penny stock is trading at 34 cents this morning. Release

> Protalix Biotherapeutics ($PLX) reports that Brazil has approved its ERT for Gaucher disease. Story

Medical Device News

 @FierceMedDev: FDA sticks Class I tag on Symbios' pump recall. Story | Follow @FierceMedDev

 @MarkHFierce: China's Dehaier Medical Systems will be one to watch in 2013 as it pursues govt. healthcare contracts at home. Story | Follow @MarkHFierce

 @DamianFierce: Third Rock Ventures-backed DC Devices hauled in another $10+ million for its heart failure device. More | Follow @DamianFierce

> NuVasive hit with FDA warning letter over spine device. More

> Johns Hopkins team takes step toward creating migraine blood Dx. Story

Pharma News

@FiercePharma: Have generics reached a saturation point? With 84% utilization, maybe. And specialty prices are soaring. Article | Follow @FiercePharma

@EricPFierce: 600,000 bottles of Glenmark's generic Singulair recalled for fishy smell. Recalls for odors not a rarity. Article | Follow @EricPFierce

> Omontys recall forces Affymax to ax 75% of workforce, weigh bankruptcy. News

> Senator questions Pfizer's $2,000-a-month price on Xeljanz. Report

> Big Pharma drools after $25B market for pricey pet care. More

Biotech Research News

@EmilyMFierce: Not to alarm anyone, but new research suggests that the black plague may still be a threat today. Post | Follow @EmilyMFierce

> Protein points to hormone therapy-resistant prostate cancer. Report

> Stem cell treatment could accelerate diabetic wound healing. Story

> Mount Sinai gets $5M from NIH to study neurological voice condition. Item

> Scripps, Takeda renew pact to find CNS treatments. More

Pharma Manufacturing News

> Claris a buyout candidate as shortages remake injectables biz. Item

> AmerisourceBergen gets Walgreen, Boots biz. Story

> FDA now inspecting 'high risk' compounders. News

> Lilly warehouse thieves followed risk-assessment 'road map.' Report

And Finally… The Alzheimer's Association says that one in three elderly Americans now dies with the memory-wasting disease. Story


Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.